Industry Overview

North America dipeptidyl peptidase 4 (DPP-4) inhibitors market was valued at $2.9 billion in 2025 and is projected to reach $3.9 billion by 2035, growing at a CAGR of 3.0% during the forecast period (2026–2035). The North America DPP-4 inhibitors market is experiencing measured growth, supported by sustained clinical reliance on oral therapies for type 2 diabetes management. Prescribing patterns reflect continued confidence in this drug class for patients requiring stable glycemic control. Broad integration within treatment regimens has reinforced its role in long-term disease management. Strong healthcare infrastructure and consistent availability across care settings have supported ongoing utilization. Physician familiarity and established clinical outcomes have contributed to steady prescription volumes.

Market Dynamics

Stable Demand for Established Oral Antidiabetic Therapies

The North America DPP-4 inhibitors market continues to show steady demand, supported by the long-term use of established oral antidiabetic treatments. Clinicians across the region maintain confidence in DPP-4 inhibitors due to their consistent glycemic control and favorable safety outcomes. Their suitability for combination therapy has reinforced prescribing continuity in routine clinical practice. Widespread availability through hospital and retail pharmacy networks has ensured sustained patient access. Ongoing monitoring and follow-up care have further supported treatment adherence. These factors collectively contribute to stable market performance across North America.

Increased Utilization in Personalized Diabetes Treatment Approaches

The market is also benefiting from the growing emphasis on personalized treatment strategies for type 2 diabetes. DPP-4 inhibitors are increasingly selected for patient groups requiring balanced efficacy with lower risk of adverse effects. Healthcare providers are aligning therapy choices with individual patient profiles, supporting continued utilization of this drug class. Advancements in clinical data and real-world evidence have reinforced confidence in long-term use. Integration into structured diabetes management programs has expanded therapeutic adoption. This trend is strengthening the market outlook across North America.

Market Segmentation

• Based on the drug type, the market is segmented into sitagliptin and vildagliptin, saxagliptin, linagliptin, gemigliptin, anagliptin, teneligliptin and others.

Sitagliptin Segment to Lead the Market with the Largest Share

Sitagliptin continues to play a significant role in the expansion of the North America DPP-4 inhibitors market. Its established clinical performance has supported consistent prescribing across diverse patient populations. Healthcare professionals value its predictable outcomes and compatibility with existing treatment protocols. Strong presence across hospital systems and outpatient care settings has reinforced utilization. Long-term familiarity among clinicians has contributed to sustained prescription levels. These factors have collectively supported steady market growth associated with Sitagliptin in the region.

Linagliptin: A Key Segment in Market Growth

Linagliptin has contributed meaningfully to market development within the North America DPP-4 inhibitors segment. Its clinical profile has supported adoption among patients requiring stable glucose management. Prescribers have increasingly incorporated Linagliptin into routine treatment pathways. Broad availability through established distribution channels has improved patient access. Continued inclusion in clinical practice has strengthened its market presence. As a result, Linagliptin remains an important contributor to regional market expansion.

Regional Outlook

North America dipeptidyl peptidase 4 (DPP-4) inhibitors market is further divided by countries, including China, Japan, South Korea, India, Australia & New Zealand, ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, and others), and the Rest of North America.

US Dominates the Market with Major Share

The DPP-4 inhibitors market in the United States is demonstrating consistent growth, supported by steady utilization within diabetes care frameworks. Treatment continuity and long-term patient management strategies have reinforced demand for this drug class. Physicians continue to rely on these therapies for maintaining controlled outcomes in routine practice. Well-developed healthcare infrastructure has ensured uninterrupted access across care settings. Ongoing clinical evaluation has sustained confidence in therapeutic use.

Market Players Outlook

The major companies operating in the North America dipeptidyl peptidase 4 (DPP-4) inhibitors market include AstraZeneca PLC, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc., and Pfizer Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In July 2025, Azurity Pharmaceuticals, Inc. announced the availability of BRYNOVIN (sitagliptin) oral solution, a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. BRYNOVIN is not recommended in patients with type 1 diabetes and has not been studied in patients with a history of pancreatitis. BRYNOVIN, which was approved by the U.S. Food and Drug Administration (FDA) in January 2025, is the first and only oral liquid sitagliptin for the management of type 2 diabetes mellitus in adults in conjunction with diet and exercise.

The Report Covers

• Market value data analysis of 2024 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the North America dipeptidyl peptidase 4 (DPP-4) inhibitors market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.